[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reports it purchased 4,314,000 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. The company intends to hold the purchased shares as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares, of which 18,887,545 are treasury shares, leaving 8,933,466,103 ordinary shares with voting rights. Shareholders may use the voting-rights figure to determine notification obligations under the FCA Disclosure Guidance and Transparency Rules. A full breakdown of individual trades is available via the provided RNS link and on the company website.

Positive

• Execution of buyback: Completed purchase of 4,314,000 shares under the announced programme
• Treasury holding: Shares will be held as treasury, preserving future flexibility for company use
• Regulatory transparency: Trade-level breakdown published in accordance with Market Abuse Regulation

Negative

• None.

Insights

Equity Analyst

TL;DR: Share repurchase modestly reduces outstanding voting stock and signals capital return to shareholders.

The announced purchase of 4,314,000 shares, held as treasury, reduces the number of shares with voting rights to 8,933,466,103. For investors this is a straightforward execution of the second tranche of the buyback program and indicates management is deploying capital to return value. The disclosure includes a trade-level breakdown via RNS in line with market-abuse transparency rules, enabling verification of execution prices and volumes. No earnings or debt information is provided to assess funding or broader financial impact.

Corporate Governance Expert

TL;DR: Procedural disclosure meets regulatory transparency; treasury holding affects voting base.

The filing clearly states intent to hold purchased shares as treasury, which preserves flexibility for future use such as employee schemes or cancellations. The updated counts for registered capital, treasury shares, and voting shares provide necessary inputs for shareholder notification thresholds under FCA rules. The company references a public breakdown of individual trades, satisfying Market Abuse Regulation reporting requirements. The report contains no information on buyback funding source or impact on capital allocation beyond the share counts.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	19 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

19 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 4,314,000 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	18 September 2025	18 September 2025	18 September 2025
Number of Shares purchased:	3,374,000	940,000	-
Highest price paid per Share (p):	344.4500	342.0000	-
Lowest price paid per Share (p):	340.2000	340.2000	-
Volume weighted average price paid per Share (p):	341.8544	341.2133	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 18,887,545 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,933,466,103 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/9590Z_1-2025-9-18.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 19, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLNCF) buy under the second tranche?

The company purchased 4,314,000 ordinary shares of £0.01 each.

Will Haleon hold the repurchased shares or cancel them?

Haleon intends to hold the purchased shares as treasury shares.

What is the number of Haleon shares with voting rights after this buyback?

After settlement the number of ordinary shares with voting rights is 8,933,466,103.

Where can I find the detailed breakdown of the individual trades?

A full breakdown is available via the RNS link: http://www.rns-pdf.londonstockexchange.com/rns/9590Z_1-2025-9-18.pdf and on the company's investor website.

Does this filing disclose how the buyback was funded?

The filing does not provide any information on the funding source for the buyback.